BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Clinical Data Completes Acquisition Of Icoria, Inc. (Formerly Paradigm Genetics) (ICOR)


12/21/2005 12:53:15 PM

NEWTON, Mass.--(BUSINESS WIRE)--Dec. 20, 2005--Clinical Data, Inc. (NASDAQ:CLDA) today announced that it has closed its previously announced acquisition of Icoria, Inc. following the approval of the merger by the stockholders of Icoria. The terms of the Agreement and Plan of Merger include the exchange of each outstanding share of Icoria common stock for 0.01552 shares of Clinical Data common stock. Effective immediately, Icoria will cease trading on the OTC Bulletin Board under ticker symbol ICOR.OB. In conjunction with the acquisition, G. Steven Burrill will join Clinical Data's board of directors effective immediately, bringing the total number of directors to eight. Mr. Burrill was Chairman of Icoria's board.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES